Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

ompleted Phase I study of bavituximab in combination with chemotherapy in patients with advanced cancer at the 2008 ASCO Annual Meeting.

Bavituximab Anti-Viral Program

The company continued to advance its bavituximab anti-viral program and was awarded a major government contract to assess the potential of bavituximab in viral hemorrhagic fevers.

-- Entered into a five-year contract potentially worth up to $44.4 million with the Department of Defense's DTRA to evaluate bavituximab for the prevention and treatment of viral hemorrhagic fever infections.

-- Continued to enroll and dose patients in an ongoing Phase I clinical trial of bavituximab in HCV patients co-infected with HIV.

-- Reported two major studies that were published in the journal Science, which highlighted the key role of phosphatidylserine (PS) in viral infections. Peregrine's bavituximab is an anti-PS agent.

-- Was awarded two patents granting Peregrine broad anti-viral method claims using a range of phosphatidylethanolamine (PE) binding agents, including PE-binding peptides attached to anti-viral agents as well as those conjugated to antibodies or other substances. These patents are a potentially valuable complement to other Peregrine anti-phospholipid programs.

Cotara(R) Brain Cancer Program:

Peregrine advanced the Cotara brain cancer program during the quarter.

-- Presented data from the Cotara dosing and dosimetry study at the ASCO 2008 Annual Meeting showing that Cotara concentrates in the brain tumor rather than affecting healthy organs. This data confirms a key safety attribute of Cotara -- its ability to precisely target tumors. All of the patients in the cohort presented have already surpassed the expected median survival time for relapsed GBM patients.

-- Continued to enroll and dose patients in the Phase II safety and efficacy trial and in the Phase I dosing and dosimetry trial in patients with GBM, the deadliest form of
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
(Date:8/29/2014)... August 29, 2014 Three Lawrence ... 2014 Hydrogen Production R&D Award for ... splitting water using sunlight. , Shared with collaborators ... the University of Nevada, Las Vegas (UNLV), the ... models of photoelectrochemical solar-hydrogen production and corrosion processes. ...
(Date:8/28/2014)... August 28, 2014 Best Sanitizers, Inc., ... the food processing industry, is asking industry professionals to ... comparison of the E2 soap they’re currently using to ... Soap . Hand hygiene is critical to fighting ... processing environment. Six key criteria are identified to evaluate ...
Breaking Biology Technology:International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Livermore Team Awarded for Hydrogen Production Research 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... am ET, 9:00 am CT, LENEXA, Kan., April ... will release its financial results for the,third quarter of ... will,host a teleconference call at 10:00 am Eastern Time ... There will be a question-and-answer,session directly following the presentation ...
... DIEGO, April 29 Cardium Therapeutics,(Amex: CXM ... today that,InnerCool,s endovascular Celsius Control System was featured ... segment (episode 5) aired April,25, 2008, and is ... 11:30 p.m.,(ET/PT) on May 9, 2008. Please visit, ...
... Bristol-Myers Squibb,Company (NYSE: BMY ) announced today that ... notes: $600 million in aggregate principal amount of,5.450% notes ... principal amount,of 6.125% notes due May 1, 2038 in ... LLC, J.P. Morgan Securities Inc., and Morgan,Stanley are acting ...
Cached Biology Technology:Mediware to Report Third Quarter 2008 Financial Results on Tuesday, May 6th 2Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University 2Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University 3Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University 4Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University 5Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford University 6Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes 2
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
(Date:9/1/2014)... About 50 years ago, electron microscopy revealed the ... move around and disappear. But scientists still don,t know ... collections of proteins are believed to be crucial to ... a new approach to disease treatment., In the ... a call to investigators from various backgrounds, from biophysics ...
(Date:8/31/2014)... the highly infectious bacteria C. diff , that ... by a team at the University of Leicester. , ... that it is possible to identify the unique ,smell, ... rapid diagnosis of the condition., What is more, the ... different strains of the disease simply from their smell ...
Breaking Biology News(10 mins):Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3Scientists call for investigation of mysterious cloud-like collections in cells 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... A study in the January 3 issue of the ... the risk of hereditary retinoblastoma survivors developing specific subtypes ... persists for decades after the original retinoblastoma diagnosis. The ... these patients, the authors say. , Retinoblastoma is ...
... of scientists has discovered that the ubiquitous bacteria that ... the human digestive system since modern man migrated from ... today (7 February) by the journal Nature, not only ... also offers a new way to study the migration ...
... from Wake Forest University School of Medicine are the ... changes in prostate and breast cancer cells that may ... imply that emotional stress may contribute to the development ... cancer treatments," said George Kulik, D.V.M., Ph.D., an assistant ...
Cached Biology News:Study examines risk of soft tissue sarcomas in hereditary retinoblastoma survivors 2Prehistoric origins of stomach ulcers uncovered 2Stress may help cancer cells resist treatment, research shows 2
... CE 4100 high pressure pump with ... with software drive compensation, reducing pulsing to ... selectable in 0.001mL steps. , The pump ... bio-compatible., Pumps may be programmed from their ...
... filter paper sandwiches are composed of a ... of thick filter paper that are preassembled ... sandwich. These 7 x 8.5 cm membrane ... Ready Gel-sized gels and are supplied as ...
... assay kit I provides reagents and a protein ... of reducing agents and detergents. The RC DC ... includes reagents and standards sufficient for 500 standard ... RC reagent II, 250 ml alkaline copper tartrate ...
... is a state-of-the-art separation system using the ... The Eclipse integrates easily with Wyatts multi-angle ... as well as the Optilab DSP. The ... mass distributions of the particles/molecules separated by ...
Biology Products: